单片复方制剂帮助更多患者控制高血压
Single-pill combination helps more patients control hypertension
一项在牙买加和哥伦比亚进行的随机临床试验显示,单片复方制剂在控制高血压方面比多片疗法更有效,降低了患者血压,并提高了依从性和满意度。
研究显示单片复方制剂在控制高血压方面更有效,有助于提高患者依从性和满意度。
Antihypertensive medications combined into a single pill lowered blood pressure more effectively than typical treatment with multiple pills for patients in Jamaica and Colombia, a study co-led by UT Southwestern Medical Center researchers shows.
The findings, shared during the Late-Breaking Science presentations at the 2026 American Heart Association Scientific Sessions held in Chicago Nov. 6–9 and published concurrently in JAMA, establish the long-term effectiveness and safety of this approach for treating uncontrolled high blood pressure.
"Our study demonstrated that a single-pill combination provided an effective, implementable, scalable and sustainable approach for hypertension control in low- and middle-income countries," said Jiang He, chair of epidemiology in the Peter O'Donnell Jr. School of Public Health and professor of internal medicine and neurology at UT Southwestern.
"It improves patients' adherence to medication and satisfaction with medication and hypertension-related care. The trial also provides additional evidence for physicians to recommend this treatment to patients with high blood pressure in the U.S. and beyond."
High blood pressure, also known as hypertension, is the leading preventable risk factor worldwide for a bevy of conditions including cardiovascular disease, chronic kidney disease, stroke and dementia, as well as for death from any cause. Although the prevalence of hypertension has decreased in high-income countries over the past several decades, it has increased in low- and middle-income countries.
Uncontrolled hypertension is a major public health challenge worldwide. Only 22.5% of patients with hypertension in the U.S. have their blood pressure controlled. More concerning, this figure drops to 13.6% in low- and middle-income countries.
Current U.S. and global guidelines recommend single-pill combination therapy as the preferred treatment strategy. This approach lowered blood pressure more and faster than multi-pill regimens in several clinical trials while offering additional benefits, including the convenience of taking just one pill and fewer side effects. However, He explained, most of these trials lasted only a few weeks, leaving it unclear whether this strategy can control hypertension over the long term.
To answer this question, He co-led the Caribbean and South American Team-Based Strategy to Control Hypertension (CATCH) randomized clinical trial with colleagues in Colombia, Jamaica and the U.S. The trial lasted four years, including recruitment of 1,706 patients with uncontrolled hypertension who were treated at 40 primary care clinics in Colombia and Jamaica.
In half of the clinics, patients received the standard care to treat this condition, mainly a strategy known as "stepped care." In this model, patients start on a single antihypertensive drug, with physicians increasing dosages and adding more drugs over time if hypertension remains uncontrolled.
In the other half, patients took a polypill that combined two or three antihypertensive medications. In addition, nurses taught these patients how to measure blood pressure at home with study-supplied equipment and regularly reviewed their results. A health coach also trained them on improving medication adherence.
After 18 months, results showed that taking the single-pill combination lowered patients' systolic blood pressure (the top number in a standard blood pressure reading) by an average of about 19 points, while those receiving usual care only had a 9-point decrease. Nearly 70% of the single-pill group reached the trial's goal of systolic blood pressure below 130 mm Hg and diastolic blood pressure (the lower number in a standard blood pressure reading) below 80 mm Hg; only 29% of the standard care group met this benchmark.
Six months after the trial ended, 75% of patients in the intervention group were still receiving single-pill combination treatment covered by their health insurance or government programs and maintained better blood pressure control, suggesting that the single-pill combination strategy is sustainable.
Only about 10% of patients with hypertension are treated with single-pill combination therapy in the U.S., He said. Physician surveys suggest this divergence from guidelines stems from unfamiliarity with this treatment option as well as a lack of evidence from large, long-term clinical trials.
While the CATCH trial partially fills this gap, He added, more large clinical trials evaluating the effects of single-pill combination therapy on clinical outcomes are urgently needed to persuade physicians and patients to widely adopt this approach for hypertension control.
Publication details
Jose P. Lopez-Lopez et al., Implementation of Single-Pill Combination Therapy Through Team-Based Care for Hypertension Control in Resource-Constrained Settings, JAMA (2026). DOI: 10.1001/jama.2026.24169
Journal information: Journal of the American Medical Association
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Single-pill combination helps more patients control hypertension (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-pill-combination-patients-hypertension.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com